Recently, several studies have shown successful use of plerixafor for PBSC mobilization in patients with multiple myeloma and renal failure; 5 --7 and its use has increased since approval in 2009 in patients with multiple myeloma and non-Hodgkin's lymphoma. There are almost no published long-term data using plerixafor in patients with AL amyloidosis and end-stage renal disease, as prior phase-III approval trials excluded patients with serum creatinine levels greater than 2.2 mg/dL. Additionally, none of the US or European compassionate use of plerixafor programs included patients with renal failure. The majority of patients with amyloidosis are successfully mobilized with G-CSF alone and plerixafor should be reserved only for those who fail G-CSF-primed mobilization. Upfront chemotherapy plus G-CSF mobilization is not a standard among large centers transplanting these patients. 1,2,8 --10 Plerixafor for PBSC mobilization in 21 patients with advanced renal failure from 15 European and US centers, that included 1 patient with primary amyloidosis was published recently by Douglas et al., 5 where all 21 patients ultimately mobilized a transplantable PBSC dose. The study did not report the long-term survival and disease-control data after auto-SCT.
We have also successfully used plerixafor, in a 48-year-old male patient with AL amyloidosis presenting with end-stage renal disease, who was diagnosed on renal biopsy during the work-up for chronic kidney disease. Echocardiogram on presentation showed findings of cardiac amyloid, but the patient had no cardiac symptoms. His BM biopsy revealed moderately hypocellular marrow with a mild increase in plasma cells and confirmed the presence of amyloid deposit in the BM. He was initially treated with melphalan and prednisone for two cycles with only minimal improvement in renal function and was then treated with five cycles of velcade and dexamethasone. He successfully mobilized PBSC (3.22 Â 10 6 CD34 þ cells/kg) with G-CSF (10 mcg/kg/day) and plerixafor (0.16 mg/kg for creatinine clearance o50 mL/min) after previously failed mobilization with G-CSF alone. The fact that the patient initially received melphalan may have contributed to the reduced yield of stem cells with G-CSF alone. No adverse events were reported during G-CSF and plerixafor mobilization. He received a melphalan auto-SCT, followed by kidney transplantation from his spouse after recovering from auto-SCT. He is now 17 months post auto-SCT, in remission, with normal renal and cardiac profiles and has returned to his full-time job. The use of plerixafor in the context of patients with AL amyloidosis and renal failure on dialysis, (either upfront or after initial failed G-CSF mobilization), has not been well reported in the literature. This is a very important observation, especially for young patients who could be delivered effective therapy to control what is otherwise considered a lethal disease.
Our recently published study showed that CY þ G-CSF stem cell mobilization has a lower rate of ideal outcome, with a higher incidence of significant adverse events and higher costs compared with mobilization with plerixafor and G-CSF mobilization. 4 Several previous studies have shown that absolute lymphocyte count (ALC) recovery early post-auto-SCT is a powerful prognostic indicator for survival for hematologic malignancies. 11 A study by Porrata et al., 12 have shown ALC-15 (ALC day þ 15 after auto-SCT) X500 cells/mL is associated with significantly improved clinical outcomes following auto-SCT in patients with systemic amyloidosis. All their patients underwent stem cell mobilization with either G-CSF alone or CY þ G-CSF mobilization regimen.
A strong correlation has been reported between the infused lymphocyte cell dose in the graft the and early post-auto-SCT ALC recovery.
11,13,14 Porrata et al., 12 have confirmed this strong correlation in patients with amyloidosis. In their study, patients with ALC-15 X500 cells/mL, received higher numbers of infused lymphocytes in the graft compared with patients achieving ALC o500 cells/mL (median-infused lymphocytes: 0.89 Â 10 9 lymphocytes/kg (range, 0.57 --2.8 Â 10 9 lymphocytes/kg) vs 0.43 Â 10 9 lymphocytes/kg (range, 0.02 --0.95 Â 10 9 lymphocytes/ kg), respectively). Our patient received a very high absolute infused lymphocyte dose (53.1 Â 10 9 lymphocytes) in the graft, and also enjoyed excellent ALC-15 recovery (970 cells/mL) after auto-SCT following plerixafor þ G-CSF mobilization.
Data have shown that the mobilization regimen influences the cellular subsets collected and infused for auto-SCT and these regimens may determine lymphocyte recovery and eventually outcome following auto-SCT. 15 Enhanced mobilization regimens such as high-dose CY with G-CSF, widely used to maximize CD34 þ collection, facilitate early engraftment and decrease the number of aphereses to mobilize stem cells for chemotherapy-treated patients. Data have shown that CY þ G-CSF stem cell mobilization is associated with a three-fold decrease in T-cell counts in the apheresis product compared with G-CSF mobilization. 16 Plerixafor has been used in many myeloma and lymphoma patients who failed G-CSF or CY-G-CSF mobilization or as a frontline mobilization regimen in heavily pre-treated patients who are candidates for auto-SCT. In an animal model, this regimen not only increased the CD34 þ cell yield, but also CD123 þ (IL-3 receptor) expression when compared with G-CSF alone. Lymphocyte engraftment was accelerated in animals receiving the G-CSF and plerixaformobilized CD34 þ cells. 17 It is possible that plerixafor may, therefore, similarly improve graft quality and clinical outcome in patients after auto-SCT. If the stem cell product contains higher activated-effector cells, such as natural killer cells, cytotoxic T cells and cytokine-induced killer cells, their presence may improve immune recovery, and possibly outcome, following auto-SCT.
An ongoing study at our institution is comparing graft composition and its relation with post-transplant lymphocyte recovery and long-term outcome after different stem cell mobilization regimens for patients receiving auto-SCT. Given the good initial safety and efficacy experience using plerixafor in myeloma patients with renal failure, it is time to study plerixafor in clinical trials as an upfront PBSC mobilization regime in patients with AL amyloidosis to improve graft composition and outcome.
